Regulation of CCL2 Expression by an Upstream TALE Homeodomain Protein-Binding Site That Synergizes with the Site Created by the A-2578G SNP by Page, Stephen H. et al.
Regulation of CCL2 Expression by an Upstream TALE
Homeodomain Protein-Binding Site That Synergizes with
the Site Created by the A-2578G SNP
Stephen H. Page
1,2, Edward K. Wright Jr
4, Lucio Gama
2, Janice E. Clements
2,3*
1McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 2Department of
Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 3Department of Neurology,
Pathology and Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 4The Henry M. Jackson
Foundation for the Advancement of Military Medicine, Washington, D. C., United States of America
Abstract
CC Chemokine Ligand 2 (CCL2) is a potent chemoattractant produced by macrophages and activated astrocytes during
periods of inflammation within the central nervous system. Increased CCL2 expression is correlated with disease progression
and severity, as observed in pulmonary tuberculosis, HCV-related liver disease, and HIV-associated dementia. The CCL2
distal promoter contains an A/G polymorphism at position -2578 and the homozygous -2578 G/G genotype is associated
with increased CCL2 production and inflammation. However, the mechanisms that contribute to the phenotypic differences
in CCL2 expression are poorly understood. We previously demonstrated that the -2578 G polymorphism creates a TALE
homeodomain protein binding site (TALE binding site) for PREP1/PBX2 transcription factors. In this study, we identified the
presence of an additional TALE binding site 22 bp upstream of the site created by the -2578 G polymorphism and
demonstrated the synergistic effects of the two sites on the activation of the CCL2 promoter. Using chromatin
immunoprecipitation (ChIP) assays, we demonstrated increased binding of the TALE proteins PREP1 and PBX2 to the -2578
G allele, and binding of IRF1 to both the A and G alleles. The presence of TALE binding sites that form inverted repeats
within the -2578 G allele results in increased transcriptional activation of the CCL2 distal promoter while the presence of
only the upstream TALE binding site within the -2578 A allele exerts repression of promoter activity.
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Introduction
Chemokines are small proteins (8–10 kDa) that function as
chemoattractants to facilitate the migration of immune cells during
immune surveillance and periods of inflammation [1,2]. CC
Chemokine ligand 2 (CCL2; formerly referred to as monocyte
chemoattractant protein 1 [MCP-1] recruits monocytes, T-
lymphocytes, and basophils to sites of inflammation where further
stimulation and production of CCL2 is amplified by a feed-
forward cycle [3,4,5,6,7,8,9,10]. Increased production of CCL2
leads to monocyte-rich infiltrates in organ specific diseases,
including the brain, and elevated levels of CCL2 are observed in
cerebral spinal fluid in a number of CNS diseases [11,12,13,
14,15,16]. Overproduction of CCL2 in the myocardium and
pulmonary arteries of transgenic mice led to myocarditis and
pulmonary vascular inflammation [17]. While overproduction of
CCL2 leads to disease progression and severity in inflammatory
related pathologies, underproduction leads to immune deficiencies
in transgenic mice as demonstrated in CCL2 knockout mice
challenged with S. pneumoniae [18].
CCL2 is a three-exon gene located at 17q11.2-q12, which is
regulated by distal and proximal promoters, each separated by
approximately 2.2 kb of DNA [3,4,6,7,8,9,19,20,21,22,23]. The
gene product is a small secretory chemokine expressed by
macrophages, lymphocytes, and activated astrocytes, and is
actively produced in response to stimuli from cytokines, growth
factors, and lipopolysaccharides. The relationship between
increased CCL2 expression and disease progression and severity
has been linked to a single nucleotide polymorphism (SNP) located
at position -2578 in the distal promoter of CCL2 in diseases such
as pulmonary tuberculosis, HCV-related liver disease, and HIV-
associated dementia [14,24,25,26,27].
Previously, we reported that following activation of human
astrocytes with IL-1b, reporter constructs containing the distal
promoter for CCL2 comprising the -2578 G allele had a greater
fold induction as compared to the A construct in functional assays
[28]. Additionally, we reported that the A-2578G SNP within the
CCL2 distal promoter forms a 6-bp site for binding of members of
the Three Amino Acid Loop Extension (TALE) protein family,
which are transcription factors involved in patterning processes in
vertebrates [29]. We also demonstrated that two members of this
family, PREP1/PBX2, form complexes and bind this site [28].
PBX2 contains a nuclear localization signal (NLS), and when it
dimerizes with PREP1, this signal mediates nuclear localization of
PREP1 [30]. In addition, PREP1/PBX2 dimers and PBX2 alone
form complexes with the homeobox protein HoxA9 [31]. The
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created by the -2778G SNP is located within an interferon-
stimulated response element (ISRE) and has been reported to bind
in-vitro transcribed and translated interferon regulatory factor (IRF)
1 in gel shift assays [25].
In this study, we modeled proinflammatory conditions by
activating astrocytes with IL-1b that results in transcription of the
CCL2 gene and secretion of the CCL2 protein as previously
described. We demonstrated the binding of PREP1, PBX2, IRF1
and HoxA9 to the CCL2 distal promoter in both the -2578 A and
G alleles via chromatin immunoprecipitation (ChIP) assays.
Binding of the TALE proteins to the -2578 A allele was
unexpected. However, TALE binding sites are often found in
multiple copies, orientations, and spacing, or as inverted repeats
[32]. Thus, we analyzed the distal promoter sequence of CCL2
and identified an inverted TALE binding site located on the
opposite DNA strand 22 bp upstream of the TALE binding site
containing the A-2578G polymorphism. We have characterized
the binding of the TALE proteins PREP1 and PBX2 as well as
HoxA9 and IRF1 to the upstream TALE site in the context of
both the -2578 A and G alleles, and we propose a new mechanism
for the role of TALE sites and the A-2578G polymorphism in the
regulation of CCL2 transcription.
Results
Interactions between the CCL2 distal promoter and
PREP1, PBX2, HoxA9 and IRF1
Using ChIP analysis, we measured the interactions between the
TALE proteins and the distal CCL2 promoter containing either
the -2578 A allele or the -2578 G allele. A human astrocytoma cell
line (U87-MG) was activated with IL-1b and transfected with
firefly luciferase constructs containing a 929 bp fragment repre-
senting the distal CCL2 promoter with either the -2578 A allele or
the -2578 G allele. In all experiments, U87-MG cells were
activated with IL-1b and produced CCL2 (data not shown). ChIP
analysis was followed by quantitative PCR (qPCR; Figure 1A).
The binding of transcription factors to the DNA constructs was
calculated as a percentage of total DNA precipitated (as described
in materials and methods) by a specific antibody and converted to
a fraction of the total as described previously (i.e. A/(A+G) or G/
(A+G)) [33]. The TALE proteins bound to a greater extent to the -
2578 G allele than to the -2578 A allele (Table 1). In addition, we
found that there was significantly greater binding of HoxA9
protein and increased binding of IRF1 to the -2578 A allele
(Table 1). Increased binding of the TALE proteins to the -2578 G
allele was expected since the SNP creates a TALE binding site
(Figure 1A); however, it was surprising that the -2578 A allele
bound to TALE proteins, PREP1 and PBX2, as well as HoxA9
and IRF1. This prompted us to look at the CCL2 distal promoter
more carefully and led us to identify an upstream TALE site
present in both alleles.
siRNA-mediated silencing of PREP1 and PBX2 alters TALE
site protein occupancy for the -2578 G allele
Since the TALE proteins had a higher percentage of binding to
the -2578 G allele, we examined the binding of PREP1 and PBX2
individually and together to the CCL2 distal promoter with the -
2578 G allele. U87-MG cells were co-transfected with siRNA and
a Firefly Luciferase construct containing a 929 bp fragment with
the -2578 G allele. Western blot analyses were used to quantitate
the efficiency of PREP1 (protein expression reduced 61% by
PREP1-siRNA) and PBX2 (protein expression reduced 97% by
PBX2-siRNA) silencing (Figure 1B). ChIP was performed on
siRNA-treated samples and data are presented as the percentage
of the total DNA that was immunoprecipitated with each antibody
for the -2578 G allele. The percentage of immunoprecipitated
DNA with anti-PREP antibody was reduced by silencing of
PREP1, PBX2 or a combination of PREP1 and PBX2 (Figure 1B).
In contrast, silencing of PREP1 protein expression had little effect
on the amount of DNA immunoprecipitated with anti-PBX2
antibody. However, the amount of immunoprecipitated DNA was
significantly reduced with silencing of PBX2 or a combination of
PREP1 and PBX2 (Figure 1C). These data are consistent with
previous studies that demonstrate that PREP1 requires dimeriza-
tion with PBX2 prior to nuclear localization and that the absence
of PBX2 prevents nuclear localization and DNA binding of
PREP1 [30]. Since PBX2 has been shown to dimerize with other
transcription factors, such as HoxA9 [31], it is not surprising that
silencing PREP1 does not reduce PBX2 binding to the -2578 G
allele. The results confirm that the TALE proteins PREP1 and
PBX2 bind to the -2578 G allele and that PREP1 binding is
dependent on PBX2.
Identification of an upstream TALE binding site repeat
The observation that the -2578 A allele bound PREP1 and
PBX2 suggested that the CCL2 distal promoter contains either a
TALE site or another site that could bind these proteins. Site
selection experiments performed by Shen et al. demonstrated that
the TALE binding sequence TGACAG is usually found in
multiple copies with varying spacing, and they frequently form
inverted repeats [32]. Based on the results above, we inspected the
region proximal to the -2578 polymorphism and identified a
second TALE binding site 22 bp upstream of the A-2578G
polymorphism (Figure 2A). Site-directed mutagenesis was used to
mutate the upstream TALE binding site from TGACAG to
TGATAG within the CCL2 promoter constructs containing the -
2578 A and G alleles. This mutation is equivalent to the A-2578G
polymorphism that had been shown previously to reduce PREP1/
PBX2 binding of the TALE binding site [28]. ChIP was
performed and the results are presented as the percentages of
total DNA precipitated by specific antibodies for either the -2578
A allele or the -2578 G allele (presence of the upstream TALE site
mutation designated either Am or Gm) [33]. Mutation of the
upstream TALE site reduced binding by both PREP1 and PBX2
for both the -2578 A and G alleles (Figure 2B, C, F and G). While
the percentage of DNA bound by either PREP1 or PBX2
decreased proportionately for both the -2578 A and G alleles when
the upstream TALE site is mutated, the amount bound to the G
allele was consistently higher than bound to the A allele when the
upstream TALE site is intact. The percentages of total DNA
precipitated by the G allele with PREP1 and PBX2 antibodies
were 0.43 and 0.58, respectively, as compared to the A allele (0.23
and 0.37,respectively). These data suggest that the upstream
TALE site plays an important role in binding TALE proteins in
both the A and G alleles and the presence of the downstream site
created by the -2578 SNP increases overall binding of TALE
proteins to the distal CCL2 promoter.
Since HOXA9 protein has been shown to form complexes with
PBX2 is was not surprising that mutation of the upstream TALE
site significantly reduced the amount of CCL2 promoter DNA
immunoprecipitated by HoxA9 antibody for both the -2578 A and
-2578 G alleles (Figure 2D and H) as was found above for binding
of PREP1 and PBX2. However, HOXA9 was found associated
with the A allele at greater levels than the -2578 G allele (%
immunoprecipitated 0.60 and 0.28, respectively). This suggests
that protein complexes associated with the A allele interact with
HoxA9 to a greater extent than those of the G allele. When the
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reduction in CCL2 promoter DNA immunoprecipitated by
HoxA9 antibody is greater in the context of the A allele
(Figure 2D, 25.2 fold) as compared to the G allele (Figure 2H,
6.75 fold). This suggests that the protein associations dependent on
the upstream TALE site in the A allele are crucial for HoxA9
interaction.
Finally, immunoprecipitation of the distal CCL2 construct with
the mutation in the upstream TALE site with IRF1 antibody
significantly reduced the percentage of DNA precipitated for only
the -2578 A allele (Figure 2E). While the A and G alleles bind
IRF1 equally when the upstream site is intact, mutation of the
upstream TALE site leads to a 15-fold (Figure 2E) decrease in
binding of the A allele as compared to a 1.5-fold decrease for the G
allele (Figure 2I). Since the upstream TALE site is not within an
ISRE, this suggests that protein/protein interactions at the
upstream site are responsible for the IRF1 binding to the A allele.
In contrast, the G allele is within an ISRE site, and binding to the
Table 1. Percentage of total CCL2 promoter DNA
immunoprecipitated: -2578 A relative to -2578 G.
Precipitating Antibody -2578 A -2578 G Standard Deviation
PREP1 39 61 9.275
PBX2 45 55 21.58
HoxA9 74 26 13.21
IRF1 55 45 9.357
ChIP results from U87-MG cells transfected with -2578 A and G containing
plasmids and activated with IL-1b for 3 hours. Results represent the
proportional binding of each transcription factor to the -2578 A and -2578 G
relative to the total DNA precipitated by each indicated antibody (A/A+Go rG /
A+G). Anti-IgG antibody was used as a negative control. The standard deviation
is the same for both the -2578 A and -2578 G values since their sum is equal to
100. Therefore, the standard deviation is listed only once.
doi:10.1371/journal.pone.0022052.t001
Figure 1. Distinct TALE site binding preferences for PREP1, PBX2, HoxA9 and IRF1 in the CCL2 promoter. ChIP results from U87-MG
cells transfected with appropriate plasmids (as described above) and activated with IL-1b for 3 hours. A. Western blot results from U87-MG cells
transfected with indicated siRNAs. GAPDH represents loading control. B,C. ChIP results from U87-MG cells co-transfected with the -2578 G pGL4.11
plasmid and indicated siRNA. Graphics show percent of total DNA immunoprecipitated by each indicated antibody. IgG represents the negative
control. Results are expressed as the mean 6 S.E. of three independent experiments carried out in duplicate. Differences between multiple groups
were tested using ANOVA (Figure 1B, P=0.0115 and Figure 1C, P=0.0014). Subsequent pair wise comparisons of groups with each treatment against
the control group utilized the Bonferroni correction.
doi:10.1371/journal.pone.0022052.g001
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overall IRF1 binding to the distal promtor. Altogether, the data
suggest that the upstream TALE site in the A allele contributes to
the binding of HOXA9, while in the G allele both TALE sites
contribute to binding of IRF1.
PREP1 and PBX2 differentially regulate transcription of
the distal regulatory region containing the A-2578G
polymorphism
To elucidate the effects of the upstream TALE site on
transcriptional activity, U87-MG cells were transfected with firefly
luciferase constructs containing the distal CCL2 promoter element
(929 bp fragment) of either the -2578 A allele or the -2578 G
allele. The cells were co-transfected with either PREP1 siRNA,
PBX2 siRNA, a combination of PREP1 and PBX2 siRNAs, a
non-targeting, control siRNA, or no siRNA. Transcriptinal
activity of the -2578 A allele increased following silencing of
PREP1 and PBX2 (Figure 3A). In contrast, when both PREP1 and
PBX2 were silenced, there was no change in promoter activity.
Conversely, silencing PREP1, PBX2, or both PREP1 and PBX2
significantly decreased promoter activity of the -2578 G allele
(Figure 3B). These data suggest that the upstream TALE site in the
-2578 A allele has a suppressive effect on transcriptional activity
when either PREP1 or PBX2 is present. However, when both
TALE proteins are limiting, other transcriptional proteins appear
to suppress the activity of the -2578 A allele. In contrast, the TALE
proteins, PREP1 and PBX2, activate the -2578 G containing the
two TALE sites. Taken together these results suggest that the
single upstream TALE site suppresses transcriptional activity while
the TALE site inverted repeats in the -2578G SNP serve to
activate the CCL2 distal promoter.
To further examine the transcriptional effects of the TALE sites
in the context of the A and G alleles on the promoter activity, cells
were also transfected with firefly luciferase reporter constructs
containing the distal CCL2 promoter with a mutated version of
the upstream TALE site in the -2578 A or G alleles. The promoter
activity of the mutated -2578 A allele (Am) was 2.2-fold higher than
that of the -2578 A allele, supporting a role in the transcriptional
repression of the distal promoter (Figure 3C). However, when the
upstream TALE site is mutated in the -2578 G allele there is only a
modest increase (p=0.26) in promoter activity (Figure 3D). These
data confirm the observations above that the single TALE site in
the context of the -2578 A allele suppresses transcriptional activity
of the distal promoter while the upstream TALE site does not have
as strong an effect in combination with the downstream TALE site
in the -2578 G allele.
Figure 2. Distinct TALE site binding preferences for PREP1, PBX2, HoxA9 and IRF1 in the CCL2 promoter with and without TALE site
repeats. A. Sequence of double stranded CCL2 promoter DNA representing the distal regulatory region containing the two TALE binding sites (in
red) with the A-2578G polymorphism within parentheses and the incorporated mutation within the upstream TALE site (denoted by *m). The CCL2
ISRE sequence is within the black box. Graphics show the percent of total DNA immunoprecipitated from U87-MG cells by each indicated antibody.
B-I. U87-MG cells were transfected with either the -2578 A pGL4.11 plasmid or the -2578 Am pGL4.11 plasmid. F-I. U87-MG cells were transfected
with either the -2578 G pGL4.11 plasmid or the -2578 Gm pGL4.11 plasmid. Percent input was calculated by 10062‘(Ctinput –C t enriched). Input was
determined from 1% of the cell lysate and results are expressed as the mean 6 S.E. of three independent experiments carried out in duplicate.
doi:10.1371/journal.pone.0022052.g002
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In this study we have identified DNA/protein interactions
between the CCL2 distal promoter and the TALE family
transcription proteins, PREP1 and PBX2 and HoxA9 a binding
partner of the TALE proteins as well as IRF1 in both the -2578 A
and G alleles. While studies have associated the A-2578G
polymorphism in the distal promoter of CCL2 with the
progression and severity of numerous inflammatory related
diseases [34,35,36], the mechanisms responsible for differential
regulation of the -2578 A and G alleles are not well understood.
Our observation that the TALE proteins bind to the -2578 A allele
suggested that an additional TALE binding site might be present
in the CCL2 distal promoter and led us to identify another TALE
binding site 22 bp upstream of the A-2578G polymorphism. We
found that the upstream TALE site in the -2578 A allele
suppressed the transcriptional activity of the distal promoter, and
suppression was relieved when the site was mutated. In
comparison, the presence of the upstream site in the -2578 G
allele had little effect on overall transcriptional activity suggesting
that the upstream TALE site was not suppressive in the context of
the TALE site repeats.
These data suggest that the single TALE site in the -2578 A
allele in the CCL2 distal promoter maintains a lower level of
transcriptional activity during inflammation while the SNP at -
2578 creates an additional TALE site that acts synergistically with
the upstream site, relieves the suppression of the single site, and
results in a higher level of transcriptional activity of the CCL2
promoter, particularly, during inflammation. We propose that the
differential effects of the two sites are likely due to a protein
Figure 3. siRNA silencing of PREP1 and PBX2 in transfected U87-MG cells differentially affects promoter activity of the -2578 A and
G alleles. A,B. Luciferase expression in U87-MG cells transfected with either the -2578 A pGL4.11 plasmid or the -2578 G pGL4.11 plasmid along with
indicated siRNAs. C. Luciferase expression in U87-MG cells transfected with either the -2578 A pGL4.11 plasmid or the -2578 Am pGL4.11 plasmid. D.
Luciferase expression in U87-MG cells transfected with either the -2578 G pGL4.11 plasmid or the -2578 Gm pGL4.11 plasmid. All results were
normalized to Renilla luciferase values. Results are expressed as the mean 6 S.E. of three independent experiments carried out in duplicate.
Differences between multiple groups were tested using ANOVA (Figure 3A, P=0.0495 and Figure 3B, P,.0001). Subsequent pair wise comparisons of
groups with each treatment against the control group utilized the Bonferroni correction. Student’s two-sided t tests were used for 3C and 3D.
doi:10.1371/journal.pone.0022052.g003
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site. In the wildtype -2578 A allele, this results in suppression of
transcription and lower levels of CCL2 expression. In the -2578 G
allele, the SNP creates a downstream TALE site and the
suppression is relieved, leading to more transcription and CCL2
expression. This explains the increased levels of CCL2 in
individuals who are homozygous for the -2578 G allele.
PREP1/PBX2 complexes have been reported to both activate
and repress promoters containing TGACAG motifs in a cell-type
dependent manner [37,38]. This may explain the reason that the -
2578 G allele has been reported to have various effects on CCL2
expression in different disease models [24,25,39,40,41,42,43].
These differences may be due to cell-type specific regulation of
CCL2 transcriptional regulators and their binding partners.
HoxA9 is a unique homeodomain protein with the capability of
forming cooperative DNA binding complexes with PBX and
PREP1 [31]. In this study, we have demonstrated increased
binding of HoxA9 for the -2578 A allele as compared to the G
allele. However, binding of both alleles is significantly reduced
(25.16-fold reduction for -2578 A and 6.75-fold reduction for -
2578 G) following mutation of the upstream TALE binding repeat.
This suggests that a complex containing HoxA9 preferentially
binds the upstream site and the presence of the downstream TALE
site in the -2578 G allele may regulate HoxA9 binding stability to
the upstream TALE site. This, in turn, would result in lower
overall binding and explain the increased binding to the -2578 A
allele.
Previously, IRF1 was reported to bind to an ISRE binding site
within the -2578 A allele in gel shift assays [25]. In this report, we
corroborated these observations, showing that DNA/protein
interactions at both the upstream TALE site and the -2578G
SNP TALE site contribute to the binding of IRF1 to the CCL2
distal promoter. We also demonstrated increased binding of IRF1
to the -2578 A allele compared to the -2578 G allele and
demonstrated by mutation of the upstream site that both TALE
sites contribute to IRF1 binding.
Two NFkB sites are located approximately 50 bp and 80 bp
upstream of the TALE site repeats and IRF1 has been shown to
interact with NFkB in both gel shift assays and co-immunopre-
cipitation experiments [44]. If TALE proteins assist in opening the
chromatin for NFkB access then the loss of the -2578 site, within
the A allele, could limit access to neighboring NFkB sites, which
would effectively reduce IRF1 access to the distal promoter and
ultimately lead to a loss in promoter activity. Conformational
changes in chromatin structure may also modulate TALE site-
mediated regulation of the distal and proximal CCL2 promoter.
For instance, induction of CCL2 by TNFa leads to conformational
changes in the CCL2 promoter facilitating interactions between
the two distal NFkB sites and a proximal Sp1 site [6]. A
conformational change of this kind may also allow regulatory
factors occupying distal TALE sites to interact with proximal
factors coordinating CCL2 transcription. However, it is important
to note that the -2578G SNP in the CCL2 promoter is the
mutation that causes increased expression of CCL2 protein both in
vivo in individuals that have the SNP as well as in monocytes and
lymphocytes isolated from those individuals compared to those
that have either the -2578A homozygous allele or the A/G
heterozygous allele [45,46,47]. Thus in the context of the entire
CCL2 promoter the -2578G SNP shows a dominant role in the
context of the NFKB sites.
The degree to which CCL2 is produced is critical as the
overproduction of CCL2 may lead to severe inflammation while
underproduction can result in suppression of the immune
response. In the case of HIV infection, CCL2 facilitates the
recruitment of uninfected cells to areas of infection within the
brain where infected monocytes may spread the virus [48]. The
resulting activation and inflammation contribute to disease
severity and progression. Overproduction of CCL2 is also known
to increase blood brain barrier permeability, another factor
associated with CNS infiltration and inflammation. We have
shown that the A-2578G polymorphism creates a second TALE
site that relieves suppression of a previously unidentified upstream
TALE site and results in increased expression of CCL2. This
provides a mechanism explaining the connection between the -
2578 G allele, increased CCL2 levels, and disease severity.
Materials and Methods
Plasmid Construction
Luciferase expression plasmids containing the distal promoter
region were cloned as previously described [28]. Briefly, the
929 bp CCL2 promoter region was amplified by PCR from
genomic DNA extracted from U937 cells for the -2578 G pGL4.11
construct (heterozygous A/G) and 293T cells for the -2578 A
pGL4.11 construct (homozygous A/A). Sequencing identified
appropriate CCL2 distal promoter pGL4.11 clones.
Site-directed mutagenesis
Mutations involving a TALE-specific nucleotide of the CCL2
distal promoter were generated using QuikChange XL site-
directed mutagenesis kit according to the manufacturer’s instruc-
tions (Stratagene). Briefly, 20 ng of the distal promoter pGL4.11
vectors (described in plasmid production) were used as a template
along with the following mutated nucleotide primers: Forward, 59
–AGGGCATCTTTTCTTGATAGAGCAGA-39 and Reverse,
59-CCCACTTCTGCTCTATCAAGAAAAGA-39. PCR condi-
tions were: predenaturing at 95uC for 1 min, followed by 18 cycles
of denaturing at 95uC for 50 s, annealing at 60uC for 50 s, and
extension at 68uC for 5 min and concluded with 68uC for 7 min.
After digestion with DpnI, 2 ml of PCR product were used to
transform XL10-Gold competent cells provided with the kit.
Sequencing identified appropriate clones.
Cell Culture
The human astrocytoma cell line U87-MG was acquired from
American Type Culture Collection (ATCC, HTB-14), (Manassas,
VA) and were maintained in MEM with glutamine supplemented
with 10% FBS, 0.1 mM nonessential amino acids (MEM NEAA),
and 1 mM sodium pyruvate. In all experiments, U87-MG cells
were activated for 3 hours with recombinant Human IL-1b (201-
LB) obtained from R&D Systems (Minneapolis, MN, USA) as
described below.
Transient transfections
DNA Transfections were described previously [28]. Briefly,
U87-MG cells in T-75 flasks were transfected with either the -2578
A pGL4.11 plasmid or the -2578 G pGL4.11 plasmid and a
pGL4.74 Renilla plasmid (Promega) for normalization control
using Lipofectamine 2000 obtained from Invitrogen Corporation
(Carlsbad, CA, USA). Transfected cells were incubated for
24 hours and activated with IL-1b for 3 hours prior to harvest.
For experiments using siRNA, cells were initially transfected with
siRNAs (50 nM; none, Risc-free siGlo, Non-targeting siRNA pool,
PKNOX1 (PREP1), and PBX2 pool) using Hyperfect. Transfected
cells were incubated for 6 hours at 37uC then media was changed
to fresh MDM 10. Transfection was repeated along with plasmid
transfection (as desribed above) after incubation for 24 hours at
37uC. Transfected cells were incubated for an additional 24 hours
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prior to harvest. ON-TARGETplus siCONTROL Non-targeting
pool (D-001810-10), siGlo Risc-free (D-001600-01) and ON-
TARGETplus Human PBX2 SMARTpool (L-011746-00) siRNAs
were obtained from Dharmacon Inc. (Lafayette, CO, USA).
PREP1 siRNA (PKNOX1HSS108055).
Western Blot Analysis
Western blot analysis was performed as described previously
[28]. Briefly, whole cell extracts were isolated from U87-MG cells
transfected with siRNA. 50 mg of cell lysate was resolved on a
10% Tris-Cl Criterion gel (Bio-Rad Laboratories, Life Science
Research, Hercules, CA) and transferred to a nitrocellulose
membrane with the criterion wet transfer apparatus. Membranes
were washed 5 minutes in TBST, blocked for 20 minutes with 5%
milk, and rocked at 4uC overnight with a-PREP1 (1:2000), a-
PBX2 (1:2000), or a-GAPDH (1:5000). Secondary antibodies were
added at 1:5000 and blots were developed with SuperSignal
Westdura extended duration substrate (Pierce Biotechnology,
Rockford, IL).
Chromatin Immunoprecipitation (ChIP) Assay
ChIP assays were performed as published previously with
modifications using the Magna ChIP G Chromatin Immunopre-
cipitation kits (20–400) obtained from Millipore.Magna ChIP kit
(Millipore). PREP1 (sc 6245X), PBX2 (sc 890X), and GAPDH (sc
47724) antibodies were obtained from Santa Cruz Biotechnolo-
gies (Santa Cruz, CA, USA). HoxA9 (ab33382-100) antibody was
obtained from Abcam Inc., Cambridge, MA, USA. Antibodies
for normal mouse IgG (12–371), Briefly, 8610
6 transfected (as
described above) U87-MG cells were treated with 1% formalde-
hyde for 10 min at room temperature and neutralized with 16
glycine. Nuclei were isolated from IL-1b activated U87-MGs that
had been transfected with either -2578G or -2578A containing
vectors with and without the upstream mutation. Samples were
sonicated to obtain 500 - 800 bp DNA fragments using the
Branson sonicator for 13 12-s pulses at 45% amplitude with
1 min of incubation on ice between pulses. Approxamtely 10
6
cells were used per immunoprecipitation in a 50 mL volume and
pre-cleared with 20 mL Dynabeads protein G (Invitrogen) for
16 hours at 4uC. Pre-cleared cell lysates were incubated with
either 4 mg of anti-PREP1, anti-PBX2, anti-HoxA9, anti-IRF1 or
mouse IgG (12–371, Millipore) antibody (negative control) at 4uC
for 6 hours. Lysates were then incubated with proteinase K at
62uC for 4 hours to reverse cross-linking. Lysates were then
incubated at 95uC for 10 minutes to denature proteinase K and
DNA was isolated using silica columns. Enriched DNA was
quantified using real time quantitative PCR (qRT-PCR) by
SYBR-Green (Qiagen) with the following primers to select for
construct/insert specific DNA: Forward, 59-AGGGCATCTT-
TTCTTAATAGAGCAGA-3, and Reverse, 5-CCTTTGCATA-
TATCAGATAGTAAACAC-39. Analysis of quantitative qRT-
PCR data was analyzed using the percent input method.
Percentage of total DNA precipitated was calculated by
10062‘(Ctinput –C t enriched). Input was determined from 1% of
the cell lysate and IgG was used as a negative control.
Luciferase Assays
Luciferase assays using the pGL4.11 Firefly and pGL4.74
Renilla vectors were described previously [28]. The pGL4.11
Firefly and pGL4.74 Renilla vectors and Dual Luciferase Assay
System were obtained from Promega Corporation. U87-MG cells
were transfected with the appropriate plasmids or plasmids and
siRNAs as described above. Cells were then lysed with passive lysis
buffer (Dual luciferase assay system; Promega) and transferred to
microcentrifuge tubes and sonicated 36 for 20 seconds each at
95% amplitude in a cup horn. Then 20 mL of lysate was subjected
to the Dual luciferase assay using the Fluoroskan Ascent FL
luminometer.
Statistics
For all experiments, descriptive statistics (mean and standard
deviation) were calculated and compared among groups using
parametric methods in PRISM statistical software package. The
Student’s two-sided t test was used to compare two groups
(Figures 2B–I, 3C and 3D). Analysis of Variance (ANOVA) was
used to compare multiple groups (i.e., control and three treatments
in Figure 1B, 1C, 3A, and 3B). Subsequent pairwise group
comparisons were made using Bonferroni’s adjustment for
multiple comparisons if the overall ANOVA test was determined
to statistically significant. Statistical significance was defined as a P
value less than 0.05.
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